S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

AQST Aquestive Therapeutics Inc

3.48

-0.04 (-1.14%)

Dec 31 2024 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

03/08/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

12/06/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Alexander Schobel

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Aquestive Therapeutics Charts.

Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Aquestive Therapeutics Charts.

Aquestive Therapeutics Inc News

Form 8-K - Current report
Thursday 19 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
Thursday 19 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 2 December 2024 (1 month ago) • Edgar (US Regulatory)

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
Monday 2 December 2024 (1 month ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 27 November 2024 (1 month ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
Tuesday 12 November 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Friday 8 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 7 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 6 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 4 November 2024 (2 months ago) • Edgar (US Regulatory)

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Monday 4 November 2024 (2 months ago) • GlobeNewswire Inc.

More Aquestive Therapeutics Inc News Articles

Anavex Life Sciences

Accredited Solutions (PK)

Digital Brand Media and ... (PK)

Kraig Biocraft Laborator... (QB)

Rennova Health (CE)

Fannie Mae (QB)

Lightwave Logic

North Bay Resources (PK)

Code Green Apparel (PK)

Intergrated Cannabis Sol... (PK)

Northwest Biotherapeutics (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions